Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

In a recently published article in the journal Frontiers in Immunology, scientists have reviewed the existing literature on antiviral and anti-inflammatory efficacy of resveratrol-based inhaled formulations in preventing SARS-CoV-2 infection and reducing COVID-19 severity.

9 Jun 2021

Structural analogs of triterpenoids show strong inhibitory activity against coronaviruses

In a recent study published in the journal Pathogens, researchers carried out a molecular docking study for 17 structural analogs prepared from natural maslinic and oleanolic acids and screened them against SARS-CoV-2 main protease. They also experimentally validated the data by determining the half-maximal cytotoxic and inhibitory concentrations of each of the 17 compounds. The researchers investigated whether the compound with antiviral activity affected viral adsorption, replication, or viricidal effect using a plaque infectivity reduction assay.

9 Jun 2021

What are the challenges of SARS-CoV-2 serosurveillance in COVID-19 vaccine recipients?

An opinion paper by researchers from the US and Italy recently discussed various aspects of monitoring anti-SARS-CoV-2 antibodies before and after receiving COVID-19 vaccination to highlight the pros and cons of this monitoring strategy. This paper is published in the open-access journal Diagnostics.

9 Jun 2021

A closer look at how COVID-19 damages human lungs

A recent study conducted at the United States Department of Energy’s (DOE) Brookhaven National Laboratory provides the first atomic-level detailed model of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) envelope protein when bound to human proteins within the lungs. The study was recently published in Nature Communications.

9 Jun 2021

Cyperus rotundus medicinal plant shows promise for novel COVID-19 therapeutics

Cyperus rotundus is a plant with a history as herbal medicine, containing many chemical substances frequently found to be drug-like in character: flavonoids, terpenoids, and the like. Compounds sourced from the plant have demonstrated some inhibitory activity against HIV by modulation of the CYP3A4 enzyme, and thus in a drug lead discovery effort, Kumar et al. (July 2021) computationally screened these natural compounds against MPRO in a paper recently published to Computers in Biology and Medicine.

9 Jun 2021

Potent antibody responses to BNT162b2 COVID-19 vaccine among Japanese healthcare workers

In a paper recently uploaded to the preprint server medRxiv* by Nakajima et al. (June 4th, 2021), the antibody responses of over 2,000 Japanese healthcare workers were tracked over a period of several months, with particular regard to serum Immunoglobulin G (IgG) against the SARS-CoV-2 spike protein.

8 Jun 2021

SARS-CoV-2 B.1.1.345 variant carrying E484K mutation detected in New York

The report, published in the journal Clinical Infectious Diseases, revealed that the variant detected has been spreading at an alarming rate since November. By February 2021, it accounted for 12.3 percent of all cases in the area.

8 Jun 2021

Increased primary healthcare need for up to six months in children post-COVID-19

A new medRxiv* preprint describes the increasing use of primary healthcare among these children even after the acute phase of COVID-19, with pre-schoolers showing the most prolonged rise in primary healthcare visits.

8 Jun 2021

SARS-CoV-2 immunity persists for up to 11 months after natural infection

The study, published in the Journal of Infectious Diseases, determined how circulating antibody levels change after being infected with SARS-CoV-2.

8 Jun 2021

COVID-19 projections after California's reopening

A new medrxiv* preprint shows how important equitable and widespread vaccination is in preventing a resurgence of cases and deaths once restrictions on social interactions are lifted.

8 Jun 2021

Antihistamines might be effective in long-COVID

A team of scientists from the United Kingdom has recently revealed the therapeutic benefits of histamine receptor antagonists in reducing long-term symptoms of coronavirus disease 2019 (COVID-19). They have also indicated that T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection vary between asymptomatic COVID-19 and long-COVID.

8 Jun 2021

Vaccination after prior infection elicits broadly neutralizing antibodies to SARS-CoV-2

A new medrxiv* preprint reports on the current landscape of vaccine-induced antibodies in the United Kingdom.

8 Jun 2021

How SARS-CoV-2 variant B.1.1.7 adapted to evade innate immunity

Researchers in the United States and the UK have conducted a study showing how the B.1.1.7 (Alpha) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) adapted to suppress host innate immune responses in lung epithelial cells.

8 Jun 2021

Researchers identify a novel host-directed therapeutic approach to COVID-19

Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).

8 Jun 2021

MIT researchers develop a molecular assay to detect sub-picomolar levels of the SARS-CoV-2's receptor-binding domain

A team of researchers at MIT has developed a molecular assay to detect sub-picomolar levels of the SARS-CoV-2’s spike protein receptor-binding domain (S-RBD) using computationally validated peptide beacons in a single-step detection through the production of a fluorescence signal.

8 Jun 2021

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

People aren’t the only ones who should be social distancing — new research shows our cells need to as well. Researchers from Ohio State University in Columbus, Ohio, USA, used in-culture techniques to confirm SARS-CoV-2 transmission via cell-to-cell contact.

8 Jun 2021

NIH researchers find that the SARS-CoV-2 Nsp15’s uridine cleavage can evade the immune response

Research conducted by scientists at the National Institutes of Health in the USA shows that Nsp15 targets uridines (U). Following detection of U, Nsp15 can then further cleave a broad spectrum of RNA substrates.

8 Jun 2021

What lessons have we learned over a year into the COVID-19 pandemic?

One of the pressing questions scientists are currently trying to answer is whether the current vaccines will remain effective against the emerging SARS-CoV-2 variants of concern. A new piece of research has been published in the journal Biomedicines, which discusses the knowledge we have gained thus far and the questions that researchers should address in future work.

8 Jun 2021

What is the role of monoclonal antibody therapy in treating COVID-19?

A new study has been published in the journal Vaccines that deals with the present state of research on using mAbs for the treatment of the COVID-19 disease. Many clinical trials are being conducted to evaluate the efficacy and safety of several newly designed mAbs. Some of the mAbs are directed towards immune system responses, i.e., non-SARS-CoV-2 specific mAbs, while others are devised to neutralize the SARS-CoV-2 protein structure, i.e., SARS-CoV-2 specific mAbs.

8 Jun 2021

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

A new study has been published in the journal Vaccines that summarizes the history of vaccines, reviews the current progress in COVID-19 vaccine technology, and discusses the status of intranasal COVID-19 vaccines as a potential pathway to immunization.

8 Jun 2021

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

Structural analogs of triterpenoids show strong inhibitory activity against coronaviruses

What are the challenges of SARS-CoV-2 serosurveillance in COVID-19 vaccine recipients?

A closer look at how COVID-19 damages human lungs

Cyperus rotundus medicinal plant shows promise for novel COVID-19 therapeutics

Potent antibody responses to BNT162b2 COVID-19 vaccine among Japanese healthcare workers

SARS-CoV-2 B.1.1.345 variant carrying E484K mutation detected in New York

Increased primary healthcare need for up to six months in children post-COVID-19

SARS-CoV-2 immunity persists for up to 11 months after natural infection

COVID-19 projections after California's reopening

Antihistamines might be effective in long-COVID

Vaccination after prior infection elicits broadly neutralizing antibodies to SARS-CoV-2

How SARS-CoV-2 variant B.1.1.7 adapted to evade innate immunity

Researchers identify a novel host-directed therapeutic approach to COVID-19

MIT researchers develop a molecular assay to detect sub-picomolar levels of the SARS-CoV-2's receptor-binding domain

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

NIH researchers find that the SARS-CoV-2 Nsp15’s uridine cleavage can evade the immune response

What lessons have we learned over a year into the COVID-19 pandemic?

What is the role of monoclonal antibody therapy in treating COVID-19?

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in